Therapeutic effect of sorafenib on portal hypertension: research progress and mechanisms.
- Author:
Yun ZHU
1
;
Yang CHENG
;
Aimin LI
;
Rongcheng LUO
Author Information
1. TCM-Integrated Cancer Center, Southern Medical University, Guangzhou 510315, China. E-mail: zyfreemail@126.com.
- Publication Type:Journal Article
- MeSH:
Animals;
Humans;
Hypertension, Portal;
drug therapy;
Niacinamide;
analogs & derivatives;
pharmacology;
therapeutic use;
Phenylurea Compounds;
pharmacology;
therapeutic use
- From:
Journal of Southern Medical University
2014;34(1):133-136
- CountryChina
- Language:Chinese
-
Abstract:
Portal hypertension, as one of the major complications of liver cirrhosis, is a common clinical syndrome characterized by an increased portal pressure and the formation of portal-systemic collaterals. Currently no ideal therapeutic agent has been available for portal hypertension. Sorafenib is an oral tyrosine kinase inhibitor that has been shown to significantly improve blood flow dynamics, inhibit angiogenesis, reduce liver fibrosis and decrease portal pressure in the treatment of portal hypertension. The authors review the progress in the research of sorafenib in the treatment of portal hypertension and the mechanisms of its actions.
